Northwestern University Feinberg School of Medicine
Department of Medicine
Skip to main content

Allergy Immunology Clinical Trials

The following searchable list includes all the Division of Allergy-Immunology, Department of Medicine clinical trials currently looking for participants. Please feel free to contact us with inquiries about any of our ongoing research.

Trials
Anti-TSLP (AMG 157) plus antigen-specific immunotherapy for induction of tolerance in individuals with cat allergy (ITN057AD)
This trial will test whether a novel therapeutic approach, cat immunotherapy combined with an investigational new drug called MEDI9929/AMG 157 (an anti-TS…
This trial will test whether a novel therapeutic approach, cat immunotherapy combined with an investigational new drug called MEDI9929/AMG 157 (an anti-TSLP [thymic stromal lymphopoietin] antibody being co-developed by Amgen and Medimmune) can lead to lasting tolerance to cat allergen.The objective of the study is to determine whether one year of immunotherapy combined with MEDI9929/AMG 157 can induce tolerance to cat allergen.
Greenberger, Paul AllenGreenberger, Paul Allen
NCT02237196 STU00088003
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Copy
A Phase IIA, Single-Center, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy of CRTh2 Antagonist AZD1981 in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
AZD-1981 is an oral tablet drug, with two pills (20 mg each) taken three times daily (120 mg total). The…
AZD-1981 is an oral tablet drug, with two pills (20 mg each) taken three times daily (120 mg total). The drug is a selective receptor antagonist, meaning AZD-1981 binds to a receptor located on the surface of a cell and blocks other cells from binding there. Without AZD-1981, when that normally open receptor is bound to, inflammation-causing eosinophils accumulate in the area. With AZD-1981 blocking that eosinophil-recruiting binding site, the number of eosinophils at that site should theoretically decrease which should reduce inflammation and therefore improve your nasal polyp symptoms.
In order to qualify for the study you must have at least grade 2 nasal polyps in each nostril, with a total polyp score of at least 4.
Peters, Anju TripathiPeters, Anju Tripathi
NCT02874144 STU00202062
More Info

For more information on this study please contact us:

Hadzic, Amela 312 695 3530
Copy
Back to top